Monday, October 20, 2008
Novartis' Ebeling is off
Along with 550 marketing jobs in the US.
Novartis AG, the Swiss maker of the Diovan hypertension drug, changed the management of three of four business units, the second shake-up in a year as the company prepares for loss of patent protection on its best-seller.
Chief Executive Officer Daniel Vasella created the post of chief operating officer for Joerg Reinhardt, a Novartis veteran who is now head of the vaccines unit. Vasella said he will share some of the workload with Reinhardt. Thomas Ebeling (pic), chief of the consumer health unit, is leaving the company, Basel-based Novartis said today.